How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

NCT00798694

Last updated date
Study Location
Wills Eye Glaucoma Service
Philadelphia, Pennsylvania, 19107, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
21 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Age 21 or older

- Able to understand protocol and agree to 3 visits

- Any type of glaucoma

- Selective laser trabeculoplasty, Argon laser trabeculoplasty, peripheral iridotomy accepted

- Naïve: No prior glaucoma treatment (medical or surgical)

- If patient non-compliant, must be off meds 3 months

- Xalatan: At least one month use

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Both Groups: Any history of ocular surface disease


- Dry eye syndrome or prior Restasis use


- Prior ocular surgery other than cataract extractions


- Uveitis or other inflammatory disease of the eye or adnexa


- Systemic medications that might influence ocular inflammation


- Any active inflammation or infection


- Pregnancy or intention to become pregnant


- Naïve: Prior use of topical glaucoma medication unless off for 3 months.


- Use of preserved artificial tear preparations in last 30 days and more than one year
history of chronic use


- Xalatan: Prior use of Travatan or Travatan Z

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

GlaucomaEffect of Age on Latanoprost 0.005% in Patients With Glaucoma
NCT00224289
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
GlaucomaDoes Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?
NCT00799994
  1. Philadelphia, Pennsylvania
ALL GENDERS
0+
years
MULTIPLE SITES
GlaucomaHow Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
NCT00798694
  1. Philadelphia, Pennsylvania
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
Official Title  ICMJE Ocular Surface Changes With Topical Prostaglandin Analog Therapy
Brief Summary To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.
Detailed Description Two groups will be entered into this study: group 1 will be naive to treatment and group 2 will be using Xalatan for at least one month before enrollment. Both groups will be using one drop at bedtime of Xalatan in the right eye and one drop at bedtime of Travatan Z in the left eye. Both of these drops are presently on the market and approved by the FDA for treatment of lowering eye pressure. Because this study will be masked, the examining clinician will not know what study drop each patient has been using.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Masking Description:
Doctors assessing patients were masked to treatment. Patients used open label Xalantan in the right eye and Travatan Z in the left eye.
Primary Purpose: Treatment
Condition  ICMJE Glaucoma
Intervention  ICMJE
  • Drug: Xalatan
    one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
    Other Name: prostaglandin analog
  • Drug: Travatan Z
    one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
    Other Name: prostaglandin analog
Study Arms  ICMJE
  • New to Meds
    Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
    Interventions:
    • Drug: Xalatan
    • Drug: Travatan Z
  • Currently on Xalatan
    Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
    Interventions:
    • Drug: Xalatan
    • Drug: Travatan Z
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 22, 2011)
58
Original Estimated Enrollment  ICMJE
 (submitted: November 25, 2008)
80
Actual Study Completion Date  ICMJE February 2011
Actual Primary Completion Date January 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age 21 or older
  • Able to understand protocol and agree to 3 visits
  • Any type of glaucoma
  • Selective laser trabeculoplasty, Argon laser trabeculoplasty, peripheral iridotomy accepted
  • Naïve: No prior glaucoma treatment (medical or surgical)
  • If patient non-compliant, must be off meds 3 months
  • Xalatan: At least one month use

Exclusion Criteria:

  • Both Groups: Any history of ocular surface disease
  • Dry eye syndrome or prior Restasis use
  • Prior ocular surgery other than cataract extractions
  • Uveitis or other inflammatory disease of the eye or adnexa
  • Systemic medications that might influence ocular inflammation
  • Any active inflammation or infection
  • Pregnancy or intention to become pregnant
  • Naïve: Prior use of topical glaucoma medication unless off for 3 months.
  • Use of preserved artificial tear preparations in last 30 days and more than one year history of chronic use
  • Xalatan: Prior use of Travatan or Travatan Z
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 21 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00798694
Other Study ID Numbers  ICMJE 08-875
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:A manuscript has been published.
Responsible Party L. Jay Katz MD, Wills Eye
Study Sponsor  ICMJE Wills Eye
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Leslie J Katz, MDWills Eye Glaucoma Service
PRS Account Wills Eye
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP